- 04/26/2018
- The Eisai China Scholarships Program Supports China’s Education for 18 Consecutive Years
- 04/20/2018
- EISAI TO PRESENT LATEST DATA ON PERAMPANEL AND RUFINAMIDE AT ANNUAL AMERICAN ACADEMY OF NEUROLOGY MEETING
- 04/19/2018
- World’s First Bile Acid Transporter Inhibitor “GOOFICE® 5mg Tablet” Launched in Japan
- 04/02/2018
- EISAI SUBMITS SUPPLEMENTAL NEW DRUG APPLICATION TO U.S. FDA FOR FYCOMPA® AS TREATMENT FOR PEDIATRIC PATIENTS WITH EPILEPSY
- 03/23/2018
- Anticancer Agent LENVIMA® Approved for Additional Indication of Unresectable Hepatocellular Carcinoma (HCC) in Japan, First Approval Worldwide for LENVIMA for HCC
- 03/12/2018
- Innovation, Joint efforts, Defense -- Shinsei Electronics management visited Eisai (China) headquarter
- 01/11/2018
- EISAI COMPLETES CONSTRUCTION OF ORAL SOLID DOSE PRODUCTION FACILITY AT NEW SUZHOU PLANT IN CHINA
- 12/27/2017
- ANTICANCER AGENT LENVATINIB DESIGNATED FOR PRIORITY REVIEW AND APPROVAL BY CHINA FOOD AND DRUG ADMINISTRATION FOR HEPATOCELLULAR CARCINOMA
- 12/13/2017
- ARICEPT® APPROVED FOR ADDITIONAL INDICATION OF SEVERE ALZHEIMER’S DISEASE IN CHINA
- 10/31/2017
- NEW DRUG APPLICATION OF ANTICANCER AGENT LENVATINIB FOR HEPATOCELLULAR CARCINOMA ACCEPTED IN CHINA
